[{"orgOrder":0,"company":"Frontage Laboratories, Inc","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Frontage Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Frontage Laboratories, Inc \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Frontage Laboratories, Inc \/ Eisai"},{"orgOrder":0,"company":"Frontage Laboratories, Inc","sponsor":"Mira Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Frontage Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Frontage Laboratories, Inc \/ Frontage Laboratories, Inc","highestDevelopmentStatusID":"4","companyTruncated":"Frontage Laboratories, Inc \/ Frontage Laboratories, Inc"},{"orgOrder":0,"company":"Frontage Laboratories, Inc","sponsor":"Silo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"SPC-15","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Frontage Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Frontage Laboratories, Inc \/ Frontage Laboratories, Inc","highestDevelopmentStatusID":"5","companyTruncated":"Frontage Laboratories, Inc \/ Frontage Laboratories, Inc"}]

Find Clinical Drug Pipeline Developments & Deals by Frontage Laboratories, Inc

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : The agreement aims for a FDA requested 7-day safety and toxicology large animal study of its lead asset SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD).

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          May 14, 2025

                          Lead Product(s) : SPC-15

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : IND Enabling

                          Recipient : Silo Pharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Ketamir-2, a novel oral ketamine analog, is being evaluated for its potential ultra-rapid antidepressant effects in major depressive disorder with suicidal ideation and treatment-resistant depression.

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          February 04, 2024

                          Lead Product(s) : Ketamine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Preclinical

                          Recipient : Mira Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : BAN2401 (lecanemab) is the humanized IgG1 version of the mouse monoclonal antibody mAb158, which selectively binds to large, soluble Aβ protofibrils, being developed for Alzheimer's disease (AD).

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          December 12, 2022

                          Lead Product(s) : Lecanemab

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Eisai

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank